Krenn, M.* ; Wagner, M. ; Zulehner, G.* ; Weng, R.* ; Jäger, F.* ; Keritam, O.* ; Sener, M.* ; Brücke, C.* ; Milenkovic, I.* ; Langer, A.* ; Buchinger, D.* ; Habersam, R.* ; Mayerhanser, K.* ; Brugger, M.* ; Brunet, T.* ; Jacob, M.* ; Graf, E.* ; Berutti, R. ; Cetin, H.* ; Hoefele, J.* ; Winkelmann, J. ; Zimprich, F.* ; Rath, J.*
Next-generation sequencing and comprehensive data reassessment in 263 adult patients with neuromuscular disorders: Insights into the gray zone of molecular diagnoses.
J. Neurol., DOI: 10.1007/s00415-023-12101-6 (2023)
BACKGROUND: Neuromuscular disorders (NMDs) are heterogeneous conditions with a considerable fraction attributed to monogenic defects. Despite the advancements in genomic medicine, many patients remain without a diagnosis. Here, we investigate whether a comprehensive reassessment strategy improves the diagnostic outcomes. METHODS: We analyzed 263 patients with NMD phenotypes that underwent diagnostic exome or genome sequencing at our tertiary referral center between 2015 and 2023. We applied a comprehensive reassessment encompassing variant reclassification, re-phenotyping and NGS data reanalysis. Multivariable logistic regression was performed to identify predictive factors associated with a molecular diagnosis. RESULTS: Initially, a molecular diagnosis was identified in 53 cases (20%), while an additional 23 (9%) had findings of uncertain significance. Following comprehensive reassessment, the diagnostic yield increased to 23%, revealing 44 distinct monogenic etiologies. Reasons for newly obtained molecular diagnoses were variant reclassifications in 7 and NGS data reanalysis in 3 cases including one recently described disease-gene association (DNAJB4). Male sex reduced the odds of receiving a molecular diagnosis (OR 0.42; 95%CI 0.21-0.82), while a positive family history (OR 5.46; 95%CI 2.60-11.76) and a myopathy phenotype (OR 2.72; 95%CI 1.11-7.14) increased the likelihood. 7% were resolved through targeted genetic testing or classified as acquired etiologies. CONCLUSION: Our findings reinforce the use of NGS in NMDs of suspected monogenic origin. We show that a comprehensive reassessment enhances diagnostic accuracy. However, one needs to be aware that genetic diagnoses are often made with uncertainty and can even be downgraded based on new evidence.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
Publication type
Article: Journal article
Document type
Scientific Article
Thesis type
Editors
Keywords
Neuromuscular Disease ; Next-generation Sequencing ; Reanalysis; Medical Genetics; American-college; Clinical Exome; Reanalysis; Supports; Genomics; Model
Keywords plus
Language
english
Publication Year
2023
Prepublished in Year
0
HGF-reported in Year
2023
ISSN (print) / ISBN
0340-5354
e-ISSN
1432-1459
ISBN
Book Volume Title
Conference Title
Conference Date
Conference Location
Proceedings Title
Quellenangaben
Volume:
Issue:
Pages:
Article Number:
Supplement:
Series
Publisher
Springer
Publishing Place
Tiergartenstrasse 17, D-69121 Heidelberg, Germany
Day of Oral Examination
0000-00-00
Advisor
Referee
Examiner
Topic
University
University place
Faculty
Publication date
0000-00-00
Application date
0000-00-00
Patent owner
Further owners
Application country
Patent priority
Reviewing status
Peer reviewed
POF-Topic(s)
30205 - Bioengineering and Digital Health
Research field(s)
Genetics and Epidemiology
PSP Element(s)
G-503200-001
G-503292-001
Grants
Medical University of Vienna
Copyright
Erfassungsdatum
2024-01-09